- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Osteoporosis Giant cell tumour of bone Bone metastases
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 403.6KB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 80.6KB)
Denosumab – November 2025
Denosumab: Injection 60 mg in 1 mL pre-filled syringe Injection 120 mg in 1.7 mL; Stoboclo® Osenvelt® - November 2025
Last updated
5 November 2025